Pimozide

Overview

A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)

Indication

适用于急、慢性精神分裂症，对精神分裂症的阴性症状疗效较好，亦可用于治疗偏执状态、亨廷顿病、抽动秽语综合征、躁狂症、神经性厌食、青少年行为障碍等。

Associated Conditions

Delusional Parasitosis
Tics

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Electrophysiological Effects of Potential QT Prolonging Drugs	2023/02/08	NCT05716854	Phase 1	Completed	Food and Drug Administration (FDA)
Treatment for Post Acute COVID-19 Syndrome	2022/08/19	NCT05507372	Not Applicable	UNKNOWN	Applied Biology, Inc.
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)	2017/09/05	NCT03272503	Phase 2	UNKNOWN	University of Calgary
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)	2015/11/09	NCT02600741	N/A	Completed	Janssen Scientific Affairs, LLC
A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS	2015/06/04	NCT02463825	Phase 2	UNKNOWN	University of Calgary
Pharmacovigilance in Gerontopsychiatric Patients	2015/03/02	NCT02374567	Phase 3	Terminated	Hannover Medical School
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients	2014/12/04	NCT02307396	Phase 4	Completed	Technical University of Munich
Efficacy of Pimozide Augmentation for Clozapine Partial Response	2006/09/11	NCT00374244	Phase 2	Completed	Yale University
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia	2005/09/12	NCT00158223	Phase 4	Completed	Icahn School of Medicine at Mount Sinai
Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome	2000/02/25	NCT00004652	Phase 2	Completed	National Center for Research Resources (NCRR)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Pimozide	Par Pharmaceutical, Inc.	49884-347	ORAL	1 mg in 1 1	11/25/2017
Pimozide	Par Pharmaceutical, Inc.	49884-348	ORAL	2 mg in 1 1	11/25/2017

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Ecopipam Shows Breakthrough Results in Phase 3 Trial for Tourette Syndrome Treatment

5 months ago

Ecopipam demonstrated significant efficacy in Phase 3 D1AMOND study, with only 41.9% of pediatric patients experiencing relapse compared to 68.1% on placebo, marking a potential breakthrough for Tourette syndrome treatment.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access